Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Jacobsson

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
BMC Health Services Research|March 3, 2025
A feasibility study of the internet-based intervention "Strategies for Empowering activities in Everyday life" (SEE 1.0) applied for people with strokeMaria Larsson-Lund, Ida-Maria Barcheus, Maria Ranner, et al.
Cancer Biotherapy & Radiopharmaceuticals|December 23, 2009
Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude miceTom Bäck, Börje Haraldsson, Ragnar Hultborn, et al.
BMC Psychiatry|October 12, 2011
Five-year mortality in a cohort of people with schizophrenia in EthiopiaSolomon Teferra, Teshome Shibre, Abebaw Fekadu, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 18, 2011
In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapySofia Helena Linnea Frost, Tom Bäck, Nicolas Chouin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 8, 2005
Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude miceJörgen Elgqvist, Peter Bernhardt, Ragnar Hultborn, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2005
211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivoTom Bäck, Håkan Andersson, Chaitanya R Divgi, et al.
Translational Oncology|September 28, 2020
Evaluation of therapeutic efficacy of <sup>211</sup>At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancerStig Palm, Tom Bäck, Emma Aneheim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor modelHåkan Andersson, Jörgen Elgqvist, György Horvath, et al.
Schizophrenia Research|December 4, 2014
Long-term clinical course and outcome of schizophrenia in rural Ethiopia: 10-year follow-up of a population-based cohortTeshome Shibre, Girmay Medhin, Atalay Alem, et al.
BMC Psychiatry|June 3, 2014
Suicide and suicide attempts in people with severe mental disorders in Butajira, Ethiopia: 10 year follow-up of a population-based cohortTeshome Shibre, Charlotte Hanlon, Girmay Medhin, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
BMC Health Services Research|March 3, 2025
A feasibility study of the internet-based intervention "Strategies for Empowering activities in Everyday life" (SEE 1.0) applied for people with strokeMaria Larsson-Lund, Ida-Maria Barcheus, Maria Ranner, et al.
Cancer Biotherapy & Radiopharmaceuticals|December 23, 2009
Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude miceTom Bäck, Börje Haraldsson, Ragnar Hultborn, et al.
BMC Psychiatry|October 12, 2011
Five-year mortality in a cohort of people with schizophrenia in EthiopiaSolomon Teferra, Teshome Shibre, Abebaw Fekadu, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 18, 2011
In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapySofia Helena Linnea Frost, Tom Bäck, Nicolas Chouin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 8, 2005
Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude miceJörgen Elgqvist, Peter Bernhardt, Ragnar Hultborn, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2005
211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivoTom Bäck, Håkan Andersson, Chaitanya R Divgi, et al.
Translational Oncology|September 28, 2020
Evaluation of therapeutic efficacy of <sup>211</sup>At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancerStig Palm, Tom Bäck, Emma Aneheim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor modelHåkan Andersson, Jörgen Elgqvist, György Horvath, et al.
Schizophrenia Research|December 4, 2014
Long-term clinical course and outcome of schizophrenia in rural Ethiopia: 10-year follow-up of a population-based cohortTeshome Shibre, Girmay Medhin, Atalay Alem, et al.
BMC Psychiatry|June 3, 2014
Suicide and suicide attempts in people with severe mental disorders in Butajira, Ethiopia: 10 year follow-up of a population-based cohortTeshome Shibre, Charlotte Hanlon, Girmay Medhin, et al.
Pageof 11